Turn Therapeutics Inc. (TTRX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $2.98K; Additional Paid in Capital, Common StockUSD $29.89M; Retained Earnings (Accumulated Deficit)USD $-29.21M; Stockholders' Equity Attributable to ParentUSD $686.89K.
- 2026-03-31: Common Stock, Value, IssuedUSD $2.98K; Additional Paid in Capital, Common StockUSD $29.48M; Retained Earnings (Accumulated Deficit)USD $-23.36M; Stockholders' Equity Attributable to ParentUSD $6.12M.
- 2025-12-31: Common Stock, Value, IssuedUSD $2.94K; Additional Paid in Capital, Common StockUSD $28.14M; Retained Earnings (Accumulated Deficit)USD $-22.39M; Stockholders' Equity Attributable to ParentUSD $4.69M.
- 2025-09-30: Common Stock, Value, IssuedUSD $2.80K; Additional Paid in Capital, Common StockUSD $23.22M; Retained Earnings (Accumulated Deficit)USD $-22.67M; Stockholders' Equity Attributable to ParentUSD $504.02K.
Turn Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.98K | $29.89M | $-29.21M | $686.89K | 6 month · $700.06K | (m) |
| 2026-03-31 | $2.98K | $29.48M | $-23.36M | $6.12M | 3 month · $280.83K | (m) |
| 2025-12-31 | $2.94K | $28.14M | $-22.39M | $4.69M | 12 month · $419.25K | (m) |
| 2025-09-30 | $2.80K | $23.22M | $-22.67M | $504.02K | (m) | 9 month · $162.87K |
| 2025-06-30 | (m) | (m) | (m) | $1.77M | 6 month · $123.78K | (m) |
| 2025-03-31 | (m) | (m) | (m) | $818.71K | 3 month · $76.60K | (m) |
| 2024-12-31 | $2.68K | $19.02M | $-19.20M | $-177.43K | 12 month · $352.83K | (m) |
| 2024-09-30 | (m) | (m) | (m) | $-414.30K | (m) | 9 month · $315.02K |
| 2023-12-31 | (m) | (m) | (m) | $85.77K | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |